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Abstract
Background—Cognitive impairment is found in a significant proportion of patients with heart 
failure (HF). While cognitive impairment may be a consequence of HF, early signs of cognitive 
impairment may also indicate subclinical vascular disease, and thus a risk factor for future 
cardiovascular events.
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Methods and Results—The Atherosclerosis Risk in Communities Study is a prospective 
cohort study of the development of atherosclerosis. Cox proportional hazards regression was used 
to examine the association between mean 6-year change in cognitive function and incident HF in 
7,962 white and 1,933 African-American men and women aged 46 to 70 years and free of clinical 
stroke. Scores were obtained for the Delayed Word Recall Test (DWRT), the Digit Symbol 
Substitution Test (DSST), and the Word Fluency Test (WFT). There was a significantly increased 
risk of developing HF during the mean 12.6 year-follow-up period after adjustment for age, 
gender, race, and education for those in the quartile with the greatest decline in DSST scores 
(hazard ratio (HR)=1.17, p=0.009), and in the quartile with the lowest baseline DSST scores 
(HR=1.43, p<0.001).
Conclusions—The results suggest that relatively low performance on a test of information 
processing speed may serve as an indicator of HF risk in middle age.
Keywords
epidemiology; cognition
Introduction
Heart failure (HF) is a major cause of hospitalization and mortality in the United States, 
estimated to affect over 6 million adults in 2010.1 The lifetime risk of developing HF for 
both men and women was reported to be 1 in 5 at 40 years of age in the Framingham Heart 
Study.2 Major risk factors for HF include coronary heart disease, hypertension, left 
ventricular hypertrophy, abnormal heart valves, diabetes, cigarette smoking, obesity, and 
lack of physical activity.3,4
An estimated 25 to 50% of patients with HF have cognitive impairment, with decreased 
attention and executive function, reduced processing speed, and memory loss as the most 
frequent deficits.5–7 In a systematic review of mostly cross-sectional studies including 2,937 
patients with HF and 14,848 controls, the odds ratio for cognitive impairment was 1.62 (p< 
0.0001) for individuals with HF.8 Cerebral hypoperfusion secondary to reduction in cerebral 
blood flow is suggested as the primary physiological mechanism linking HF and impaired 
cognitive function.9
While cognitive impairment may be a downstream consequence of HF, early signs of 
cognitive impairment may also be an indication of subclinical vascular disease, and thus a 
risk factor for future clinically apparent cardiovascular disease. In a previous investigation 
carried out in the ARIC study, Elkins et al. tested the hypothesis that poor performance on 
tests of cognitive function may be used to identify individuals who are particularly 
susceptible to developing myocardial infarction and stroke and found that lower cognitive 
scores predicted a greater risk of cardiovascular events over a 6.4 year period.10 Similar 
results have recently been reported for 5,292 participants in the Whitehall II study where 
lower scores on tests of vocabulary and verbal and mathematical reasoning were associated 
with an increased incidence of coronary heart disease during 6 years of follow-up,11 and in 
the Health and Retirement Study and a study of Swedish men where lower scores on tests of 
delayed word recall or executive function, respectively, were shown to predict risk of 
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incident stroke.12,13 The aim of the current study was to determine whether performance on 
three neurocognitive tests administered at baseline or change in cognitive function measured 
over 6-years were associated with incident HF in white and African-American participants 
in the ARIC study.
Material and Methods
The Atherosclerosis Risk in Communities Study
The ARIC Study is a prospective longitudinal investigation of the development of 
atherosclerosis and its clinical sequelae in which 15,792 individuals aged 45 to 64 years 
were enrolled at baseline. A detailed description of the ARIC study has been reported 
previously.14 At the inception of the study in 1987–1989, the participants were selected by 
probability sampling from four communities in the United States: Forsyth County, North 
Carolina; Jackson, Mississippi (African-Americans only); the northwestern suburbs of 
Minneapolis, Minnesota; and Washington County, Maryland. Four examinations were 
carried out at three-year intervals (exam 1, 1987–1989; exam 2, 1990–1992; exam 3, 1993–
1995; exam 4, 1996–1998), and subjects are contacted annually to update their medical 
histories between examinations. A fifth clinical examination has recently been completed 
(2011–2013). Cognitive testing was performed at visits 2, 4, and 5 in all participants. 
Individuals were not included in this analysis if they were neither African-American nor 
white (n = 48), were African-Americans from the Minnesota or Maryland field centers due 
to the small numbers of individuals recruited from these sites (n = 55), had a history of 
physician-diagnosed stroke (n = 272) or unknown history of stroke (n = 31) prior to visit 2, 
did not attend visit 2 (n = 1,432), did not attend visit 4 (n = 1,769), had HF (n = 530) or an 
unknown history of HF (n = 233) at the first clinical examination, or developed HF prior to 
the second clinical examination (n = 71) or between exams 2 and 4 (n = 631). Additional 
exclusions were made for incident definite or probable stroke verified by ARIC clinicians 
from medical records between visit 2 and 4 (n = 365), missing cognitive data for all three 
neuropsychological tests at either visit 2 or visit 4 (n = 287), if hospitalized for dementia 
prior to visit 4 and identified using ICD-9 codes (Alzheimer’s disease (331.0); vascular 
dementia (290.4); or other forms of dementia (290.0, 290.1., 290.2, 290.3, 290.9, 294.1, 
294.2, 294.8, 294.9, 331.1, 331.2, 331.8, 331.9) (n = 6), for missing information concerning 
the highest level of education completed (n =16), or for missing covariates (n = 151). The 
final study sample consisted of 7,962 white and 1,933 African-American men and women. 
Written informed consent was provided by all study participants, and the study design and 
methods were approved by institutional review boards at the collaborating medical centers.
Cognitive Tests
Cognitive function was assessed by three neuropsychological tests at the second and fourth 
clinical examinations that have been described previously15: 1) The Delayed Word Recall 
Test (DWRT) is a test of verbal learning and recent memory in which the participant is 
required to use each of 10 common nouns in a sentence. After a 5-minute delay in which 
another test is given, the participant is asked to recall the 10 nouns. The DWRT score is the 
number of correct words recalled (range 0 – 10)16; 2) The Digit Symbol Substitution Test 
(DSST) is a subtest of the Wechsler Adult Intelligence Scale-Revised involving timed 
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translation of numbers to symbols using a key with paired symbols and digits and measures 
psychomotor performance.17, 18 The total number of correct translations within 90 seconds 
determines the score (range 0 – 93)17; and 3) The Word Fluency Test (WFT) is a measure of 
executive function. In three separate 1-minute trials, the subject is asked to generate as many 
words as possible beginning with the letters F, A, and S.18 The score is the combined total of 
correct words produced.19 The tests were administered by trained interviewers in a 
standardized order and were given in a single session. The testing sessions were monitored 
by tape recorder and a sample of sessions was evaluated to confirm that there were no 
systematic differences in mean test scores obtained by different interviewers.
For all of the neuropsychological tests, lower scores indicate a lower measure of cognition. 
Six-year change in cognitive function was analyzed as the difference between the test score 
obtained at the later of the two clinic visits and the test score obtained at the earlier 
examination for each neuropsychological test.
Clinical and Laboratory Measurements
The clinical and laboratory measurements used for this study were assessed during the 
second clinical examination with the exception of education which was evaluated at the 
baseline examination. Education was included as a covariate in regression models as an 
ordinal variable based on the highest level attained (≤ 11 years; 12 −16 years; > 17 years). 
Incident HF was defined as the first HF hospitalization (ICD-9 code 428 in any position), or 
any deaths where the death certificate included a HF code (code 428, ICD-9 or 150, ICD-10, 
in any position). Exclusion for HF was based on self-reported current medication use for HF, 
or having manifest HF as defined by Gothenburg criteria stage 3. The Gothenburg criteria 
are based on a cardiac score (i.e., history of coronary heart disease, angina, or atrial 
fibrillation), pulmonary score (i.e., history of asthma or bronchitis), and therapy score (i.e., 
treatment with diuretics or digoxin). To be classified as stage 3 an individual must have at 
least 1 point from each category.20,21 Prevalent coronary heart disease was defined based on 
evidence obtained at the first clinical examination of previous myocardial infarction by 
electrocardiogram, a history of myocardial infarction that was diagnosed by a physician, or a 
prior coronary bypass or angioplasty procedure, or if the same events occurred between the 
first and second clinical examination.
Plasma total cholesterol and triglycerides were measured by enzymatic methods,22,23 and 
LDL-C was calculated.24 High density lipoprotein cholesterol (HDL-C) was measured after 
dextran-magnesium precipitation of non-HDL.25 Blood pressure was measured three times 
while seated using a random-zero sphygmomanometer and the last two measurements were 
averaged for analysis. Hypertension was defined by diastolic blood pressure of ≥ 90 mm Hg, 
systolic blood pressure of ≥140 mm Hg, or use of antihypertensive medication. Fasting 
serum glucose was measured by a standard hexokinase method on a Coulter DACOS 
chemistry analyzer (Coulter Instruments, Fullerton, CA). The prevalence of diabetes was 
defined using a fasting glucose level ≥ 7.0 mmol/L, a nonfasting glucose level ≥ 11.1 
mmol/L, and/or self-reported physician diagnosis or treatment for diabetes. Body weight and 
other anthropometric variables were measured by trained technicians according to 
standardized protocols. Body mass index (BMI) was calculated as weight in kilograms/
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(height in meters)2. Information on cigarette smoking and alcohol consumption was 
obtained using an interviewer-administered questionnaire, and smoking and drinking status 
were classified as current, former, or never. Airflow obstruction was measured by spirometry 
and was defined as forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) 
< 0.7.26 Serum creatinine was measured using a Jaffe method and calibrated to nationally 
representative estimates as previously described.27 GFR was estimated based on serum 
creatinine using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
equation (eGFRCKD-EPI) with eGFRCKD-EPI<60 mL/min/1.73m2 defined as chronic kidney 
disease.28
Statistical Analysis
All statistical analyses were performed using Stata 9 software (StataCorp, College Station, 
TX, USA). Proportions, means, and standard deviations were calculated for cardiovascular 
risk factors for individuals categorized by incident HF status. Groups were compared using 
chi square tests for categorical variables and t-tests for continuous variables. Quartiles of 
cognitive test scores at baseline or of 6-year change in cognitive test scores were generated 
that correspond to the 25th, 50th (median), and 75th percentiles of the distribution. In the 
primary analyses, Cox proportional hazards models were used to estimate hazard ratios (HR) 
for HF occurring after visit 4 for those in the quartile with the greatest cognitive decline 
between visits 2 and 4 or the lowest cognitive scores at baseline compared to study 
participants in all other quartiles for each cognitive test. In a secondary analysis, Cox 
proportional hazards models were also used to estimate HRs when individuals in quartiles 
two through four for the DSST were compared to those in the top quartile. For the analyses 
of incident HF through 2011, follow-up time intervals were defined as the time between visit 
4 and the date of the first HF event. For participants without HF, follow-up continued 
through the date of last contact, or the date of death if the date of last contact had occurred 
within one year. Study participants were followed for a mean of 12.6 years. Two 
multivariable models were used to evaluate the relationship between cognitive function and 
incident HF; model 1 was adjusted for age, gender, race and years of education, while model 
2 included the covariates in model 1 with the addition of established risk factors for HF 
including diabetes and hypertension case status, body mass index (BMI), current smoking, 
current alcohol intake, and prevalent coronary heart disease. A third model was used to 
further adjust for clinical variables (HDL-C, total cholesterol, airflow obstruction, and 
chronic kidney disease) that can affect both cognition and risk of HF,29 and were 
significantly different at baseline when individuals who developed HF were compared to 
those who did not. In secondary analyses, effect modification by race and gender of the 
association between cognitive function and incident heart failure was examined. Cox 
regression models were adjusted for the same covariates used to assess main effects and also 
included multiplicative interaction terms for gender by cognitive status or race by cognitive 
status. Analyses stratified by race and gender were performed to further evaluate possible 
interactions. Proportional hazards assumptions were met except for the Cox regression 
model used to test for interaction between race and performance on the WFT at baseline, the 
race-stratified analysis for whites for the WFT at baseline, and in the comparisons of quartile 
one with quartiles two through four for the WFT at baseline (model 1, model 2, and model 
3).30 A two-sided p-value <0.05 was considered statistically significant.
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Results
The clinical and demographic characteristics of the study sample are summarized in Table 1. 
There were 1,228 cases of incident HF among 9,895 study participants (12.4 %). The cases 
and comparison group without HF differed significantly for all demographic variables or 
cardiovascular risk factors examined. ARIC study participants who developed HF were 
older, more likely to be male, African-American, a current smoker, and to have diabetes, 
hypertension, prevalent coronary heart disease, airflow obstruction, or chronic kidney 
disease but less likely to consume alcoholic beverages than those without HF. The cases also 
had a higher body mass index, higher total and LDL cholesterol, lower HDL cholesterol, and 
higher systolic and diastolic blood pressure. In addition, the mean 6-year change in scores 
attained on the DWRT and DSST but not the WFT differed significantly between cases and 
non-cases (Table 2), with greater decline found for those individuals who were hospitalized 
for HF.
Subjects who were in the quartile with the greatest decline in scores for the DSST were 
compared to those in quartiles two through four in order to define a group who were 
performing less well than their peers in middle age when only small changes in cognitive 
status are expected. Mean cognitive scores for each quartile for each test, and for the 
individuals in quartiles two through four combined are shown in Table 3. There was a 
significantly increased risk of developing HF after adjustment for age, gender, race, and 
level of education (hazard ratio (HR) = 1.17, 95% confidence interval (CI) = 1.04 –1.32, p 
=0.009) (Table 4) that was only slightly attenuated after inclusion of diabetes, hypertension, 
smoking, alcohol consumption, and prevalent coronary heart disease as additional covariates 
in the analysis models (model 2), or after further adjustment for HDL-C, total cholesterol, 
airflow obstruction, and chronic kidney disease (model 3). There was also an increase in 
susceptibility observed for those who were in the quartile with the lowest scores for the 
DWRT (HR = 1.16, 95% CI = 1.03 – 1.30, p = 0.012) and the DSST at the baseline cognitive 
examination (HR =1.43, 95% CI =1.24 – 1.66, p < 0.001). In contrast to the results for the 
DSST, the association was no longer significant for the DWRT in the fully adjusted models. 
In a secondary analysis, the hazard ratios for quartiles two through four for the DSST were 
also compared to those for quartile one to determine whether the risk for HF decreased in a 
step-wise fashion as mean cognitive test scores increased or mean change in cognitive test 
scores decreased (Table S1 (models 1 and 2) and S2 (model 3)). This pattern was observed 
for the DSST at baseline but not for 6-year change on the DSST. Individuals in the third 
quartile had a higher risk of HF than study participants who were in either quartile two or 
four using both the minimal and fully adjusted Cox regression models.
In secondary analyses in which the association between cognitive change and incident HF 
was examined separately by gender (Table 5), the association between cognitive function as 
assessed by all three neurocognitive tests and incident HF did not appear to be modified by 
gender (all p interaction > 0.07). In stratified analyses, there was a marginally significant 
increase in risk for both men and women with the greatest decline in DSST scores using the 
minimally adjusted Cox regression model, while this association was no longer statistically 
significant after further adjustment for a panel of risk factors for HF. Both men and women 
in the quartile with the lowest DSST scores at baseline incurred a significantly increased risk 
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of HF over the follow-up period. Race-specific analyses were also carried out (Table 6). 
There was evidence for effect modification by race of the association between the risk of HF 
and change in DSST scores using both regression models, and for change in DWRT and 
WFT scores using the fully adjusted model (all p interaction < 0.05), while no significant 
statistical interaction between baseline cognitive status and race was found. Further support 
for the interaction between DSST score change and race was provided in the stratified 
analyses. In white participants, there was a significant association between risk of incident 
HF and 6-year change in DSST scores while this was not found for African-Americans 
using both the minimally adjusted and fully adjusted Cox regression models. For white study 
participants analyzed at baseline there was a significantly elevated risk of HF for those with 
the lowest DSST scores, as well as increased risk of HF for those with the lowest DWRT 
scores only after application of the minimally adjusted model. For African-Americans, there 
was increased susceptibility for the development of HF if the individual was in the quartile 
with lowest baseline DSST scores using the minimally adjusted model while this 
relationship was no longer significant after further adjustment for the panel of risk factors 
for HF.
Discussion
In this study, ARIC study participants in the quartile with the lowest cognitive scores for the 
DSST at baseline, and the quartile with the greatest 6-year change in scores for the same 
test, predicted a significantly greater risk of subsequent incident HF. All of the analyses were 
adjusted for age, gender, self-reported race, and years of education, and the associations 
were largely independent of established risk factors for HF including diabetes, hypertension, 
current smoking alcohol intake, and prevalent coronary heart disease when these were added 
to the regression models. There was no significantly increased risk of developing HF 
observed for those with the poorest performance on either the DWRT or WFT after taking 
into account the effects of covariates and possible confounders. These observations are in 
accordance with a previous report in which baseline scores on the Mini Mental State 
Examination (MMSE),31 a global screening test of cognitive function, were significantly 
associated with hospitalization for congestive HF over a 56-month follow-up period in 
patients with prior cardiovascular disease or diabetes.32 To our knowledge, the study 
reported here is the first conducted to date in which change in cognitive function was 
evaluated as a determinant of incident HF.
Performance on the DSST has previously been demonstrated to decline with normal aging.18 
Relatively lower scores on the DSST have also been shown to be associated with increased 
mortality over a 5- or 6-year follow-up period in participants in the Cardiovascular Health 
Study,33 the ARIC study,34 and the Western Collaborative Study.35 There is also evidence 
that poor performance on the DSST predicts the occurrence of myocardial infarction and 
stroke.10 Since slowing of psychomotor speed has been demonstrated to be associated with 
the presence and severity of subcortical white matter lesions,36 we speculate that poor 
cognitive function assessed by the DSST may be an early sign of vascular damage that 
precedes the development of clinically apparent HF. Accordingly, lower performance on 
tests of processing speed has been observed in patients with HF in several previous cross-
sectional studies, as well as at baseline in longitudinal studies of change in cognitive 
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function.5–7, 37–41 For example, patients with stable HF scored significantly below age- and 
education-adjusted norms on the Trail Making Test Part A when given the Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS).38 Similarly, in a 
relatively young group of 279 patients, nearly 60% of the sample had scores on the DSST 
that were below the mean at the outset of the study, and also performed significantly worse 
on tests of attention and memory when compared to subjects with average processing speed. 
There was little change in these patterns of cognitive function over the 6-month study 
period.41 It has also previously been suggested that poor performance on the DSST may be a 
marker for generalized acceleration of aging of the central nervous system.35 Alternatively, 
although the absolute change in neurocognitive test scores was relatively modest, decreased 
attention and processing speed could possibly affect compliance with treatment for 
cardiovascular risk factors such as diabetes and hypertension which when uncontrolled can 
contribute to the onset of HF.42–45 Finally, the results reported here also provide support for 
the hypothesis that since HF is a disorder involving vascular compromise, the reverse 
interpretation may also be valid and generalized vascular disease that is not confined to the 
brain could be associated with cognition.
The strengths of the study include a large well-phenotyped cohort with cognitive 
assessments repeated at multiple time points using the same standardized protocols. 
However, there are also limitations. While many risk factors that may have an impact on 
both cognition and the risk of developing HF were included in the regression models, some 
conditions were not assessed at the baseline clinical visit such as depression,29 so there may 
be some residual confounding of the reported associations. Since HF was defined using 
hospital International Classification of Diseases (ICD) codes in this study, participants with 
HF who did not seek medical attention or who had died of other causes before developing 
HF for which they may have been hospitalized would not have been identified. It is also 
possible that some participants may have had HF diagnosed in an outpatient setting or 
subclinical HF at the time cognitive function was assessed. Furthermore, a large number of 
participants were excluded from the analysis including those who did not have a second 
cognitive assessment at visit 4 (n = 1,769). When these individuals were compared to those 
who were included in the study, scores on all three cognitive tests were significantly lower at 
baseline (all p < 0.001, data not shown) so that the effects of cognitive function on HF risk 
may have been underestimated. Since the relationship between change in cognitive function 
and HF has so far not been widely examined using neuropsychological tests, the current 
study adds to our understanding of the nature and extent of cognitive decline in a large 
population-based sample of middle-aged adults, and suggests that both relatively low 
performance on a test of processing speed as well as repeated measurements of cognitive 
function may serve as an indicator of HF risk.
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Table 3
Cognitive Test Scores and 6-Year Score Change by Quartiles
Cognitive Test Baseline Cognitive Function 6-Year Cognitive Change
N Mean (SD) N Mean (SD)
DWRT (All Participants) 9,893 6.76 (1.46) 9,889 −0.14 (1.54)
    Quartile 1 4,101 5.35 (0.90) 3,915 −1,66 (0.92)
    Quartile 2 2,668 7.00 (0.00) 2,610 0.00 (0.00)
    Quartile 3 2,077 8.00 (0.00) 2,065 1.00 (0.00)
    Quartile 4 1,047 9.18 (0.38) 1,299 2.33 (0.64)
    Quartiles 2–4 5,792 7.75 (0.82) 5,974 0.85 (0.94)
DSST (All Participants) 9,880 46.77 (13.32) 9,848 −2.49 (6.85)
    Quartile 1 2,465 29.15 (7.50) 2,881 −10.01 (4.74)
    Quartile 2 2,709 43.65 (2.72) 2,708 −3.44 (1.11)
    Quartile 3 2,402 52.38 (2.30) 1,904 −0.05 (0.80)
    Quartile 4 2,304 63.46 (5.61) 2,355 5.83 (4,77)
    Quartiles 2–4 7,415 52.63 (8.95) 6,967 0.62 (4.90)
WFT (All Participants) 9,887 34.37 (12.18) 9,866 − 0.51 (7.97)
    Quartile 1 2,611 19.75 (5.33) 2,821 −9.73 (4.92)
    Quartile 2 2,528 30.48 (2.31) 2,636 −1.90 (1.40)
    Quartile 3 2,338 38.34 (2.26) 2,000 2.44 (1.12)
    Quartile 4 2,410 50.46 (6.75) 2,409 9.37 (4.69)
    Quartiles 2–4 7,276 39.62 (9.33) 7,045 3.18 (5.61)
DWRT, Delayed Word Recall Test; DSST, Digit Symbol Substitution Test; WFT, Word Fluency Test; N, number; SD, standard deviation
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Table 4
Risk of Incident Heart Failure for Top Quartile of Cognitive Function
Cognitive Test (Top Quartile) Heart Failure
N HR 95% CI p
Model 1a
Baseline*
DWRT 9,893 1.16 1.03, 1.30 0.012
DSST 9,880 1.43 1.24, 1.66 <0.001
WFT 9,887 1.12 0.98, 1.28 0.084
6-year change†
DWRT 9,889 1.04 0.93, 1.17 0.484
DSST 9,848 1.17 1.04, 1.32 0.009
WFT 9,866 1.04 0.92, 1.18 0.504
Model 2b
Baseline* 9,893 1.11 0.99, 1.25 0.075
DWRT 9,880 1.34 1.16, 1.55 <0.001
DSST 9,887 1.08 0.95, 1.24 0.230
WFT
6-year change†
DWRT 9,889 0.99 0.89, 1.11 0.905
DSST 9,848 1.15 1.02, 1.30 0.020
WFT 9,866 1.01 0.89, 1.14 0.887
Model 3c
Baseline*
DWRT 9,631 1.11 0.98, 1.25 0.095
DSST 9,620 1.34 1.16, 1.56 <0.001
WFT 9,625 1.09 0.95, 1.25 0.198
6-year change†
DWRT 9,627 0.98 0.87, 1.10 0.764
DSST 9,589 1.14 1.00, 1.29 0.044
WFT 9,605 0.99 0.88, 1.13 0.929
DWRT, Delayed Word Recall Test; DSST, Digit Symbol Substitution Test; WFT, Word Fluency Test; N, number; HR, hazard ratio; CI, confidence 
interval;
ap-value adjusted for age, gender, race, and education;
bp-value adjusted for risk factors for heart failure (covariates for model 1 + BMI, hypertension, diabetes, current alcohol consumption, current 
smoking, and prevalent heart disease);
cp-value adjusted for covariates for model 2 + total cholesterol, HDL, airflow obstruction, and chronic kidney disease;
*
comparison of quartile with lowest scores at baseline to all other quartiles;
†
comparison of quartile with greatest cognitive decline to all other quartiles
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